Will the Phase 2 trial "Phase II Study of Weekly Paclitaxel/Nab-Paclitaxel, Pembrolizumab, and Mirabegron for Recurrent Ovarian Cancer" reach primary completion on or before Nov 30, 2027?

Resolves Yes if ClinicalTrials.gov record NCT07261683 (Obstetrics & Gynecology Hospital of Fudan University) shows an actual primary completion date on or before Nov 30, 2027. Registered date at generation: Nov 30, 2027.

Outcome verified from clinicaltrials.gov.

1. Market open

   Jul 17, 2026, 7:40 AM UTC
2. Market closes

   By Nov 30, 2027, 11:59 PM UTC
3. Projected payout

   Shortly after the market closes

Trading on material non-public information is prohibited. Markets are for entertainment and informational purposes using free Pulse Credits — no real-money wagering. If you believe a participant has acted on inside information, please report it.